Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51

Authors
Lee, Jung OkKang, Min JuByun, Won SeokKim, Shin AeSeo, Il HyeokHan, Jeong AhMoon, Ji WookKim, Ji HaeKim, Su JinLee, Eun JungPark, Serk InPark, Sun HwaKim, Hyeon Soo
Issue Date
22-10월-2019
Publisher
BMC
Keywords
Cisplatin resistance; Metformin; RAD51; TNBC; Combination therapy
Citation
BREAST CANCER RESEARCH, v.21, no.1
Indexed
SCIE
SCOPUS
Journal Title
BREAST CANCER RESEARCH
Volume
21
Number
1
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/62177
DOI
10.1186/s13058-019-1204-2
ISSN
1465-5411
Abstract
Background Chemotherapy is a standard therapeutic regimen to treat triple-negative breast cancer (TNBC); however, chemotherapy alone does not result in significant improvement and often leads to drug resistance in patients. In contrast, combination therapy has proven to be an effective strategy for TNBC treatment. Whether metformin enhances the anticancer effects of cisplatin and prevents cisplatin resistance in TNBC cells has not been reported. Methods Cell viability, wounding healing, and invasion assays were performed on Hs 578T and MDA-MB-231 human TNBC cell lines to demonstrate the anticancer effects of combined cisplatin and metformin treatment compared to treatment with cisplatin alone. Western blotting and immunofluorescence were used to determine the expression of RAD51 and gamma-H2AX. In an in vivo 4T1 murine breast cancer model, a synergistic anticancer effect of metformin and cisplatin was observed. Results Cisplatin combined with metformin decreased cell viability and metastatic effect more than cisplatin alone. Metformin suppressed cisplatin-mediated RAD51 upregulation by decreasing RAD51 protein stability and increasing its ubiquitination. In contrast, cisplatin increased RAD51 expression in an ERK-dependent manner. In addition, metformin also increased cisplatin-induced phosphorylation of gamma-H2AX. Overexpression of RAD51 blocked the metformin-induced inhibition of cell migration and invasion, while RAD51 knockdown enhanced cisplatin activity. Moreover, the combination of metformin and cisplatin exhibited a synergistic anticancer effect in an orthotopic murine model of 4T1 breast cancer in vivo. Conclusions Metformin enhances anticancer effect of cisplatin by downregulating RAD51 expression, which represents a novel therapeutic target in TNBC management.
Files in This Item
There are no files associated with this item.
Appears in
Collections
Graduate School > Department of Biomedical Sciences > 1. Journal Articles
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Hyeon Soo photo

Kim, Hyeon Soo
의과학과
Read more

Altmetrics

Total Views & Downloads

BROWSE